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Background: Trastuzumab is currently approved for the clinical treatment of breast and gastric cancer patients
with HER-2 positive tumors, but not yet for the treatment of esophageal carcinoma patients, whose tumors typically
show 5~ 35% HER-2 gene amplification and 0 ~ 56% HER-2 protein expression. This study aimed to investigate the
therapeutic efficacy of Trastuzumab in patient-derived esophageal squamous cell carcinoma xenograft (PDECX)
mouse models.
Methods: PDECX models were established by implanting patient esophageal squamous cell carcinoma (ESCC)
tissues into immunodeficient (SCID/nude) mice. HER-2 gene copy number (GCN) and protein expression were
determined in xenograft tissues and corresponding patient EC samples by FISH and IHC analysis. Trastuzumab
anti-tumor efficacy was evaluated within these PDECX models (n = 8 animals/group). Furthermore, hotspot
mutations of EGFR, K-ras, B-raf and PIK3CA genes were screened for in the PDECX models and their corresponding
patient’s ESCC tissues. Similarity between the PDECX models and their corresponding patient’s ESCC tissue was
confirmed by histology, morphology, HER-2 GCN and mutation.
Results: None of the PDECX models (or their corresponding patient’s ESCC tissues) harbored HER-2 gene
amplification. IHC staining showed HER-2 positivity (IHC 2+) in 2 PDECX models and negativity in 3 PDECX models.
Significant tumor regression was observed in the Trastuzumab-treated EC044 HER-2 positive model (IHC 2+). A
second HER-2 positive (IHC 2+) model, EC039, harbored a known PIK3CA mutation and showed strong activation of
the AKT signaling pathway and was insensitive to Trastuzumab treatment, but could be resensitised using a
combination of Trastuzumab and AKT inhibitor AZD5363. In summary, we established 5 PDECX mouse models and
demonstrated tumor regression in response to Trastuzumab treatment in a HER-2 IHC 2+ model, but resistance in a
HER-2 IHC 2+/PIK3CA mutated model.
Conclusions: This study demonstrates Trastuzumab-induced tumor regressions in HER-2 positive tumors, and
highlights PIK3CA mutation as a potential resistance mechanism to Trastuzumab treatment in pre-clinical
patient-derived EC xenograft models.
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The incidence of esophageal carcinoma (EC) and the
histological type varies widely with geographical location
[1]. Notably, esophageal squamous cell carcinoma
(ESCC) is the predominant histological type in Asian
areas with a high risk of cancer development in the
esophagus, in contrast to Western countries (Northern
Europeans and Caucasians in the USA) [1]. In the
United States and North and Western Europe, where
esophageal adenocarcinoma is the predominant histo-
logical type, the incidence of ESCC has been decreas-
ing in recent decades, whilst the incidence of
esophageal adenocarcinomas, especially of the gastro-
esophageal junction, has been increasing [2,3].
Surgery remains the mainstay of therapy for esophageal
carcinoma patients. However, ESCC diagnosis is asso-
ciated with a high mortality owing to its aggressive behav-
ior and the 5-year survival for non-metastatic disease
ranges from 20% to 40% [2]. Patients with metastatic dis-
ease who are treated with palliative chemotherapy using a
combination of 5-Fluorouracil (5-FU) and Cisplatin have a
median survival of less than one year and response rates
of 25% to 45% in phase II and III trials [4,5]. Salvage
options for patients with refractory EC are very limited
[6]. Unfortunately, there are no clinically approved tar-
geted therapies for the treatment of esophageal carcinoma.
Human epidermal growth factor receptor 2 (HER-2) is
overexpressed in breast and other types of human can-
cers and has been successfully developed as a thera-
peutic target [6,7]. Antibody-based therapy with
Herceptin (Trastuzumab) has been used for the clinical
treatment of HER-2-positive breast cancer [6,7]. Re-
cently, Trastuzumab therapeutic efficacy has also been
observed in HER-2-overexpressing gastric cancer [7].
Previous studies in patients with ESCC indicated that the
frequency of HER-2 protein expression ranged from 0 to
56% [8,9], whilst the frequency of HER-2 gene amplifica-
tion ranged from 5 to 35% [8,9]. These data suggested that
a proportion of ESCC patients could be candidates for
Trastuzumab targeted therapy. Results from early clinical
trials demonstrated a correlation between HER-2 expres-
sion and gene amplification with Trastuzumab therapeutic
efficacy in patients with esophageal adenocarcinomas [10].
However, over expression and amplification of HER-2
appeared to be fundamentally different within esophageal
squamous cell carcinoma, with a tendency of lower positive
rates and lower level amplification, compared to adenocar-
cinoma [11]. Accordingly, it is not possible to imply
Trastuzumab efficacy within esophageal squamous cell car-
cinoma, and as such, these studies aimed to address this
preclinically. Therefore, we established xenograft mouse
models derived from patient’s ESCC tissues and used these
novel, clinically relevant ESCC models to explore the anti-
tumor efficacy of Trastuzumab targeted therapy.Materials and methods
Patients and tissue samples
ESCC tissues from 54 treatment-naïve patients were
obtained intraoperatively during esophagetomy resec-
tion at Zhongshan Hospital (Shanghai, China) from
March 2010 to June 2010. ESCC histology was con-
firmed by pathological analysis. Prior written informed
consent was obtained from all patients and the study
protocol was approved by the ethics committee at
Zhongshan hospital, Fudan University. Freshly har-
vested ESCC specimen was separated into three parts.
The first part was placed into medium containing anti-
biotics immediately after surgical resection under ster-
ile conditions and transported to the animal facility
within two hours for implantation into immunodefi-
cient mice. The second part of the specimen was snap
frozen immediately in liquid nitrogen for DNA/RNA
extraction. The third part of the specimen was fixed in
formalin and embedded into paraffin (FFPE) for patho-
logical and IHC analysis.
Development of patient-derived esophageal carcinoma
xenograft (PDECX) mouse models
Female nude (nu/nu) (8-10-week-old) and severe com-
bined immune deficient (SCID) mice (Vital River, Beijing,
China) were used for xenograft model generation. All
experiments with immunodeficient mice were per-
formed in accordance with the guidelines approved
by IACUC. The PDECX mouse models were estab-
lished with fresh ESCC tissues surgically removed
from EC patients. Briefly, surgically removed patient’s
ESCC tissues (F0 tissue) were cut into fragments of
approximately 15 mm3 and implanted via Trocar nee-
dle subcutaneously into female SCID mice within
two hours after the surgery. The implanted mice
were observed daily until 90 days. Tumors were mea-
sured once a week by caliper to determine its sub-
cutaneous growth. The xenografted ESCC tumors
(~500 mm3) were harvested from the patient ESCC-
bearing mice and were further implanted in female
nude mice for expansion. After three consecutive
mouse-to-mouse passages, the xenograft was consid-
ered to be stabilized and was submitted to the
process of model characterization, including histo-
pathologic analysis, HER-2 expression by FISH and
IHC assays, and mutation detection for EGFR, K-ras,
B-raf and PIK3CA genes. The xenograft tumor speci-
mens in each passage of tumor-bearing mice were
harvested and divided into three parts as same as the
patient tumor samples. Fresh tumor fragments at
passage 3–5 were frozen with 20% FCS in liquid ni-
trogen for further model recovery. The PDECX mod-
els were maintained in nude mice and were used for
anti-tumor efficacy studies.
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Tissues from all PDECX mouse models and their corre-
sponding ESCC patients were harvested and fixed in
10% buffered formalin within 30 minutes after resection.
Tissues were processed following the routine procedure
after 24 hours fixation. Sections were stained with
Hematoxylin and eosin and reviewed by a pathologist to
confirm the ESCC diagnosis. Dual cores from each case
were made on tissue microarray (TMA) for IHC and
FISH analysis. For the IHC, all incubations were at room
temperature and washes were performed with TBST.
Tissues sectioned at 4 μm onto slides were dewaxed and
rehydrated. Antigen retrieval was performed in a pres-
sure cooker at 110°C for 5 minutes in retrieval buffer
(S2367, DAKO). Endogenous peroxidase activity was
blocked with 3% hydrogen peroxide (S2023, DAKO).
Sections were then incubated with anti-HER-2 antibody
(HerceptestTM, DAKO) for 30 minutes. Immunocom-
plexes were detected by incubation with DAKO K5204
for 30 minutes and were visualized with diaminobenzi-
dine (K3468, DAKO) for 10 minutes. Normal IgG from
the same species of primary antibody diluted to match
the concentration of the primary antibody was used as
the negative control. For the HER-2 negative cases, the
experiment was repeated on the whole section in order
to exclude heterogeneity.
In the present study, the IHC scoring on EC followed
Hoffman’s criteria on human gastric cancer [12]: no
staining or <10% tumor cell positive staining were con-
sidered as 0/negative; faintly or barely perceptible stain-
ing on >10% tumor cell membrane were considered as 1+;
weak to moderate positive staining on >10% tumor cells
were considered as 2+; since tumor tissue on TMA mim-
icked the biopsy samples, cohesive moderate to strong
staining on the membrane was scored as 3+ .
HER-2 FISH assay
HER-2/CEP17 probes for Bysis (Cat #30-161060) was
used and FISH assay was performed according to the
manufacturer’s instructions. In brief, TMA sections were
dewaxed and dehydrated. Tissue samples were pre-
treated following the manual of SpotLight Tissue pre-
treatment kit (Invitrogen, Carlsbad, CA) (Cat #00-8401).
After pretreatment, 10 μl HER-2/CEP17 probes were ap-
plied onto each TMA slide, which was subsequently cov-
ered with a coverslip and circled with rubber cement
(Mpbio, Solon, OH) (Cat #11FIXO0125) around the
edge of coverslip. Sections together with probes were
codenaturated at 75°C for 4 minutes on OmniSlide In-
Situ hybridization System, followed by incubation at
37°C overnight. Probes were washed sequentially with 0.3%
NP40/1×SSC at 75.5°C for 3 min, 0.3%NP40/2×SSC at
75.5°C for 2 minutes and 2×SSC at room temperature
for 2 min, with twice for each wash. The slides werethen dehydrated and mounted with 0.3 μg/ml DAPI
mounting medium (Vector, Burlingame, CA) (Cat #H-
1200). In each case, 100 tumor nuclei were evaluated
based on Hoffmann criteria [12] and other investigator
[9]. An absolute HER-2 gene copy number lower than
four or an HER-2/Chr17 ratio of less than 1.8 was con-
sidered as negative for HER2 gene amplification. Cases
with average HER-2 gene copy number >6 or a HER-2/
CEN17 fluorescence ratio > or= 2 were considered as
positive for gene amplification. Cases with HER-2 copy
number between four and six or an HER-2/Chr17 ratio
between 1.8 and 2.0 were considered as HER-2
equivocal.
Anti-tumor efficacy of Trastuzumab treatment
Tumor growth curves were generated by kinetic meas-
urement of tumor volumes. For therapeutic experiments,
tumor-bearing mice with a tumor range of 100 to
200 mm3 were randomly divided into the vehicle control
or Trastuzumab treatment groups (8 animals per group).
The mice in the treatment group were treated with
monotherapy of Trastuzumab (Roche, China, 4 mg/kg/
twice a week intraperitoneally) or combination of Tras-
tuzumab with AKT inhibitor AZD5363 (120 mg/kg/
twice daily, orally). Subcutaneous tumors in nude mice
and mice body weight were measured twice a week.
Tumor volumes were calculated by measuring two per-
pendicular diameters with calipers. Tumor volumes (V)
were calculated by the formula: V = (length + [width]2)/2.
Percentage of tumor growth inhibition (%TGI = 1 –
[changes of tumor volume in treatment group/ changes
of tumor volume in control group] × 100) was used for
the evaluation of anti-tumor efficacy. For tumor regres-
sion, in which the tumor volume after treatment was
smaller than the tumor volume at the beginning, the fol-
lowing equation was used: regression%= 100 × (T0-Ti)/
T0, Ti and T0 was the tumor volume in the same group
but measured at the different time points. T0 is the
tumor volume on the day before first dosing of the com-
pound, and Ti is the tumor volume at the last measure-
ment day after compound treatment.
Screening of gene mutations
Formalin-fixed paraffin-embedded tumor blocks were
reviewed for quality and tumor content. A single represen-
tative block, from PDECX mouse models and the corre-
sponding patient ESCC samples, containing at least 70%
of neoplastic cells, was analysed for gene mutations. Gen-
omic DNA was extracted using the QIAamp Mini kit
(Qiagen, Valencia, CA) according to the manufacturer’s
instructions. Hotspots in exon 18, 19, 20, 21 of EGFR
gene, exon 2 and 3 of K-ras gene, exon 11 and 15 of B-raf
gene, and exon 9 and 20 of PIK3CA gene were screened
by scorpions amplification refractory mutation system
Wu et al. Journal of Translational Medicine 2012, 10:180 Page 4 of 11
http://www.translational-medicine.com/content/10/1/180(ARMS) and mutant-enriched liquid chip PCR method
[13]. The former method and detection was supported by
Amoy diagnostics Co. Ltd, Fujian, PR China, the latter
method was completed by SurExam Bio-Tech Co. Ltd.,
Guangzhou Technology Innovation Base (Science City,
Guangzhou, PR China). Positive results in both methods
were further confirmed by PCR-direct sequencing. The
primers for exon 9 of PIK3CA gene were GTCTTA
GATTGGTTCTTTCCTG for forward and GCATT
TAATGTGCCAACTACC for reverse, for exon 20 of
PIK3CA gene were TTTGTCTACGAAAGCCTCTCTA
for forward and CCATCACTTTTTCCTTCTCCAT for
reverse.
Western blot (Wb)
Total proteins were extracted with mammalian protein
extraction reagent (Beyotime, P0015, China). 80 μg of
total protein was electrophoresed in 4%-12% Criterion
XT Bis-Tris gels (Bio-Rad) and transferred to polyvinyl
difluoride (PVDF) membranes (Millipore) at 340 mA for
75 min. Membranes were blocked with 5% non-fat milk
in TBST buffer and probed with specific antibodies. All
primary antibodies were used at a final concentration of
1 μg/ml. The blots were then visualized with a chemilu-
minescent detection system as described by the manu-
facturer. Antibodies against HER-2 (#06-562) was
purchased from Upstate Biotechnology; p-Mtor-Ser 2448
(No. 2971) from DAKO Biotechnology, and mTor (No
2972), AKT (No 9272), p44/42 MAP Kinase (No 9102),
S6 (No 2317), 4EBP1 (No 9452) and p-AKT-Ser 473
(M3628), Phospho-p44/42-MAPK-Thr202/Tyr 204 (No
4370), p-S6-Ser 240/244 (No 2215), p-4EBP1-Thr 70 (No
9455), and anti-GAPDH were purchased from CST
Biotechnology.
Statistical analysis
Statistical significance was evaluated using a one-tailed,
two sample t test. P values of less than 0.05 were consid-
ered to be significant.
Results
Establishment of PDECX mouse models
Of the 54 patient ESCC tissues transplanted subcutane-
ously into immunodeficient mice, a total of 25 (46.3%)
PDECX models were successfully established. After
screening of HER-2 expression and amplification by IHC
and FISH in all 25 models, only EC039 and EC044
showed IHC 2+ for HER-2 expression. HER-2 amplifica-
tion was not identified in any of the models. EC039,
EC044 and 3 HER-2 negative models were selected for
the next experiments.
The features of the 5 ESCC patient models selected
for Trastuzumab anti-tumor efficacy testing are shown
in Table 1. Prior to surgery, all patients were treatment-naïve. Patient ESCC samples grew up in SCID mice after
subcutaneous implantation with the original patient
ESCC tissue and continued to grow up in nude mice
after a second generation with implantation of xenograft
tumor. At the time of study, these PDECX mouse mod-
els had more than 5 passages and showed different kin-
etic growth curves. The latency from implantation of
ESCC tissues to the initiation of growth in mice became
shorter with increasing passage: 61 ± 22 days in passage
1; 56 ± 28 days in passage 2; 49 ± 29 days in passage 3,
and became stable after passage 3. Figure 1 shows the
growth curves of the 5 established PDECX mouse mod-
els at passage 3. The 5 established PDECX mouse mod-
els could be divided into two groups based on latency
and in vivo tumor doubling time. Two models had short
latency periods (24 days in EC016 model, and 35 days in
EC044 model), but different tumor doubling times
(96 hours in EC016 model, and 192 hours in EC044
model). The other 3 models had longer latency periods
(74±23 days) and tumor doubling times (312 ±62 hours).
Autopsy examination of tumor-bearing mice from these
PDECX models at 2–3 months post-implantation revealed
no evidence of metastases to the stomach, brain, lung, liver
or kidney. All 5 PDECX mouse models and their corre-
sponding patient’s EC tissues were pathologically con-
firmed to be squamous cell carcinoma. Similar histological
features were observed between each xenograft model and
the corresponding patient’s ESCC tissues (data not shown).
Characterization of HER-2 expression and gene copy
number in PDECX models
Following Hoffman’ HER-2 score criteria (12), two PDECX
mouse models (EC039 and EC044) were scored as moder-
ately positive for HER-2 membrane staining (2+), the
remaining models (EC004, 016 and 054) were negative for
HER-2 staining (Figure 2). According to Hoffman’s criteria,
none of the PDECX models were identified as HER-2 gene
amplified using FISH analysis. However, models EC039
and EC044 showed increased gene copy numbers, with
average copy numbers of 3.90 and 3.92, respectively. HER-
2 expression and gene copy number were similar between
the PDECX models and their corresponding patient’s
ESCC tissues (Figure 2).
Trastuzumab antitumor efficacy in PDECX models
Trastuzumab anti-tumor efficacy was assessed in all 5
PDECX mouse models (Figure 3 and Table 1). Three
HER-2 negative PDECX mouse models (EC004, 016 and
054) showed either no or marginal responses to Trastu-
zumab treatment (ranging from 0 to 48% TGI). Only
one HER-2 negative model (EC054) showed significant
efficacy (P = 0.0004, 48% TGI). However, in the HER-2
IHC 2+ EC044 model, targeted therapy with Trastuzu-
mab induced significant tumor regression (93% tumor
Table 1 Patient and corresponding PDECX mouse model information
Patient information Characterization & anti-tumor efficacy in the Patient-derived EC xenograft models











IHC PIK3CA EGFR K-ras B-raf TGI% Tumor
regression %
P value
M/70 ESCC IIIB Moderate EC004 1.52 1.07 - - - - - 44 0 0.1333
M/61 ESCC IIA Poor EC016 2.38 1.25 - - - - - 0 0 0.3113
M/65 ESCC IIA Moderate EC039 3.92 1.26 ++ + - - - 41 0 0.2290
M/56 ESCC IIIA Moderate EC044 3.90 1.55 ++ - - - - >100 93 <0.0001
M/73 ESCC IIIA Moderate EC054 3.04 1.27 - - - - - 48 0 0.0004
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activity was not observed with Trastuzumab treatment
in a second HER-2 IHC 2+ model (EC039, p= 0.229).Gene mutation screening in PDECX models
To explore potential Trastuzumab resistance mechan-
isms in model EC039, we screened for mutations in a
panel of genes (EGFR, K-ras, B-raf and PIK3CA) across
all 5 PDECX models and their corresponding patient EC
tissues. Screened gene locations included; exons 18, 19,
20, 21 of EGFR gene, exons 2 and 3 of K-ras gene, exons
11 and 15 of B-raf gene, and exons 9 and 20 of PI3KCA
gene. Interestingly, PIK3CA G1624A (E542K) mutation
was identified within exon 9 of the PIK3CA gene helical
domain in both EC039 model and the corresponding
patient’s EC tissue. This was identified by mutant-
enriched liquid chip PCR and ARMS methods
(Figure 4a), and subsequently confirmed by direct-
sequencing (Figure 4b, c). No other mutations were
detected in these 5 PDECX mouse models and the cor-
responding patient ESCC tissues.Figure 1 Tumor growth curves of the 5 PDECX mouse models
at passage 3. Subcutaneous tumors were measured by caliper, and
median tumor volumes in 3 tumor-bearing mice from each model
are represented. X-axis represents days after tumor implantation.Western blotting for EC039 and EC044 models
Due to observing dramatically different Trastuzumab
anti-tumor responses within two xenograft models with
the same HER-2 level (2+), but differing PIK3CA muta-
tion status, we sought to determine the AKT pathway
activation states within tumor lysates from these models.
Western blotting was performed and the quantified data
represented in Figure 5A. Significant increases in the
protein levels of AKT and pAKT were observed in
model EC039 compared to model EC044 (p<0.0004).
Our data clearly demonstrate AKT pathway activation as
a consequence of PIK3CA mutation in model EC039,
compared with the PIK3CA wild type model EC044.
AKT inhibition resensitises model EC039 to Trastuzumab
therapy in vivo
To further test our hypothesis that PIK3CA mutation
was responsible for the resistance to Trastuzumab ther-
apy in a HER-2 positive esophageal PDECX model, we
performed an anti-tumor efficacy combination study
using Trastuzumab and the small molecule AKT inhibi-
tor, AZD5363 [14]. Trastuzumab monotherapy (15 mg/
kg twice weekly) resulted in a modest 45% TGI
(P= 0.003) whilst AZD5363 therapy alone (120 mg/kg
bid) gave a non-significant TGI of 10% (P= 0.281). The
combination of both agents together however, resulted
in a significant synergistic anti-tumor effect, generating
TGI of 78% (P <0.0001) (Figure 5B).
Discussion
It is well established that patient-derived xenograft
mouse models can better represent human tumors
through increased diversity of molecular lesions and the
preservation of three-dimensional tumor-stromal cell
components and interactions [15]. Although some
patient-derived xenograft models, e.g., NSCLC [16,17],
melanoma [18], colon cancer [19], breast cancer [20],
HCC [21,22], GIST [23], have been established and used
for evaluation of anti-tumor compounds [24], the avail-
ability of patient-derived EC xenograft models is limited.
Previous studies have however, developed xenograft EC
models by implanting human EC cell lines into mice
Figure 2 Representative pictures of HER-2 IHC and FISH staining on models EC004, 016, 039, 044 and 054 with matched human
primary tumor tissues. HER-2 moderate staining (++) and FISH GCN increase were detected in models EC039 and EC044 and matched primary
tumor tissues. EC004, EC016 and EC054 were shown to be HER-2 IHC negative and FISH non-AMP.
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velop novel PDECX models. After successfully establish-
ing 25 PDECX mouse models through implantation of
54 patient EC samples, 5 PDECX mouse models were
selected for evaluation of Trastuzumab anti-tumor effi-
cacy based on HER-2 expression levels. Although the
five models displayed varying growth rates (Figure 1),
this was not related to differentiation and HER-2 positiv-
ity (Table 1). Indeed, the varying growth rates of patient-
derived models are likely related (at least in part), to the
requirement to directly implant tumor fragments, rather
than standardized defined numbers of tumor cells.
Trastuzumab anti-tumor efficacy correlates well with
HER-2 expression in patients with breast [6,27-29] and
gastric cancer [7,24,30]. Esophageal carcinoma represents
another disease with a high frequency of tumor HER-2 ex-
pression and gene amplification [8,9,11]. In this setting,
the frequency of patients with tumor HER-2 positiveexpression ranges from 0 to 56% [8,9], whilst the fre-
quency of HER-2 gene amplification varies from 5% to
35% [8,9,11]. In addition, the predominant histological
subtype of esophageal carcinoma differs between Eastern
and Western countries, and adenocarcinoma has been
shown to exhibit higher rates of HER-2 protein expression
positivity and gene amplification compared to squamous
cell carcinoma [11]. Accordingly, most current preclinical
and clinical studies are focused on esophageal adenocar-
cinoma and literature data supports a correlation between
HER-2 gene expression (or amplification) and Trastuzu-
mab efficacy in esophageal adenocarcinoma (preclinical
and clinical phase I/II data [10,31] however, such data is
rare in esophageal squamous cell carcinoma [32]. In order
to address the therapeutic efficacy of Trastuzumab in
esophageal squamous cell carcinoma preclinical studies,
we characterized 5 PDECX mouse models for HER-2 gene
amplification and protein expression. In this study, we did
Figure 3 Anti-tumor efficacy of Trastuzumab in the 5 PDECX mouse models. Tumor-bearing mice were treated starting from tumor volume
100~ 200 mm3. The subcutaneous tumor volume was measured by caliper and calculated as mean± SEM. Y-axis represented the volume of the
tumor (mean± SEM), and X-axis represents the number of days following treatment start day.
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(3+) or gene amplification (FISH score≥ 6) in the 25 estab-
lished PDECX mouse models. Two PDECX mouse models
(EC039 and 044) were positive (IHC 2+) for HER-2Figure 4 PIK3CA gene mutation in model EC039 and the correspondi
confirmation of PIK3CA gene mutation in 1624 nucleotide, correspon
of PIK3CA gene by PCR-direct sequencing (b: Forward, c: Reverse).expression and had relatively high HER-2 copy number
(~3.9). HER-2 gene copy number and protein expression
were highly consistent between the 5 PDECX mouse mod-
els and their corresponding patient’s EC tissues (Figure 2),ng primary tumor identified by ARMS method (a) and
ding to codon 542 (GAA542AAA/E542K) in exon 9 helical domain
Figure 5 AKT activation in PIK3CA mutation model and AKT
inhibition desensitizes model EC039 to Trastuzumab therapy.
A. Western blot analyses of EC039 and EC044 PDECX models. Three
xenograft tumors in both PIK3CA mutation EC039 and wild type
EC044 model were harvested, and total proteins were extracted and
analyzed with the indicated antibodies. Blots were quantified by
density scanning and the graphed data (Mean+ SD) represents the
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sent clinical EC disease, compared to standard cell line-
derived xenografts.
Clinically, approximately 20% of esophageal adenocar-
cinoma patients who were HER-2 IHC 2+ and FISH
negative demonstrated a complete clinical response [10].quantification of the ratio of protein expression to GAPDH.
Significant changes (p < 0.0004) between the two models are
labeled as *. B. Combination with Trastuzumab and AKT selective
inhibitor AZD5363 in PIK3CA mutation model EC039.Mimura et al. have also demonstrated that HER-2
expressing esophageal SCC cells could be killed by
Trastuzumab-mediated ADCC and that anti-proliferative
activity reflected the degree of HER-2 expression
detected by flow cytometry, but not by HercepTest nor
fluorescence in situ hybridization analysis. To determine
if HER-2 positive (IHC 2+) and FISH negative esopha-
geal squamous cell carcinoma could be responsive to
Trastuzumab monotherapy, we tested Trastuzumab
anti-tumor efficacy in 5 established PDECX mouse
models with varying degrees of HER-2 expression and
gene copy number. Unsurprisingly, there was no tumor
regression, and no or marginal response to Trastuzu-
mab treatment in the HER-2 negative PDECX models.
Our data demonstrated that Trastuzumab induced
complete tumor regression in one of the HER-2 positive
models (IHC 2+) (Figure 3 and Table 1), but generated
no significant anti-tumor response in the other. Whilst
we believe that this potent anti-tumor effect is a direct
consequence of anti-proliferative activity, we note that
Trastuzumab has been observed to exert both mild
anti-angiogenic and anti-metastatic effects [33] how-
ever, we were unable to assess changes in these pheno-
types within the studies documented here.
To explore the underlying mechanism behind these
contrasting Trastuzumab responses, additional genetic
changes were analyzed. It is well known that some key
gene mutations including EGFR, K-ras, B-raf, PIK3CA,
often affect the efficacy of molecular-targeted therapies
[34,35]. In clinical studies of metastatic colon cancer,
patients with wild type K-ras, B-raf and PIK3CA genes
gain benefit from cetuximab therapy[34], whilst lung can-
cer patients with mutations in exons 19 and 21 of the
EGFR gene benefit from Iressa or Tarceva therapy. Fur-
thermore, mutations in ESCC patients have been recently
reported; 16% of ESCC patients (5/30 cases) harbor K-ras
gene mutations [36], 14% of ESCC patients (7/50 cases)
contain EGFR mutation [37], and 2.2-11.8% of ESCC
patients have gene mutations in exon 9 of the PIK3CA
gene [38,39]. These findings suggest that gene mutation(s)
may play a key role in resistance to Trastuzumab treat-
ment. After screening for EGFR, K-ras, B-raf and PIK3CA
gene mutations in the 5 PDECX mouse models and their
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EC039 (and the corresponding patient tissue) had a helical
domain mutation (G1624A, E542K) in exon 9 of the
PIK3CA gene (Figure 4 and Table 1). This mutation is
known to activate downstream signaling of the AKT path-
way [40,41]. As such, this result likely explains why the
HER-2 positive (IHC 2+) model EC039 was unresponsive
to Trastuzumab treatment, whilst model EC044 (HER-2
positive (IHC 2+)) displayed tumor regression. PIK3CA
activating mutations have been reported to associate with
shorter time to progression (TTP) in Trastuzumab-treated
breast cancer [42]. More recently, particular attention has
been paid to the role of the PIK3CA gene in Trastuzumab
resistance. Mutations in exon 9 and 20 of the PIK3CA
gene have been observed in 8% to 40% of breast cancers
[43-45]. Furthermore, an association between PIK3CA
mutation and resistance to Trastuzumab therapy in HER-
2-amplified breast cancer cell lines has also been reported
[46]. Berns et al. have also suggested that oncogenic muta-
tions of PIK3CA may render breast cancers more resistant
to treatment with Trastuzumab [47], and Eichhorn et al.
have further shown that mutational activation of PIK3CA
can similarly render cells more resistant to the recently
approved anti-HER2 agent Lapatinib. In this situation
however, Lapatinib resistance caused by the dominant ac-
tivating mutations in PIK3CA can be effectively reversed
by treatment with the PI3K/mTOR inhibitor, NVP-
BEZ235 [48]. Moreover, the AKT inhibitor AZD5363
increases the efficacy of lapatinib and/or trastuzumab in
xenografts derived from HER2+ breast cancer cell lines
harboring PIK3CA mutation [14]. In our study, we
observed strong AKT pathway activation in the PIK3CA
mutation model EC039 (Figure 5A) compared to wild type
model EC044, suggesting that activated AKT pathway sig-
naling likely contributes to Trastuzumab resistance in our
efficacy study. To our knowledge, we are the first to de-
scribe a PIK3CA gene mutation which causes resistance
to Trastuzumab therapy in a preclinical PDECX mouse
model, and which can be partly resensitised using a com-
bination of Trastuzumab and AKT inhibitor (Figure 5B).
The inability to achieve full tumor regression in this com-
bination study may be a consequence of only blocking
PI3K pathway signaling downstream through AKT, thus
still allowing PDK1, PKC and Rac signaling to occur.
In summary, we have established novel xenograft mod-
els derived from patient esophageal squamous cell car-
cinoma, and have used these clinically relevant animal
models to investigate Trastuzumab efficacy in HER-2
expressing ESCC. Our results demonstrate that a non-
amplified, HER-2 IHC 2+ model responds completely to
Trastuzumab targeted therapy, and importantly, that
PIK3CA gene mutation negatively associates with Tras-
tuzumab anti-tumor efficacy in a xenograft model of
ESCC. Moreover, resensitization to Trastuzumab therapyis achieved when treatment is combined with an AKT
inhibitor to suppress PIK3CA pathway signaling. Taken
together, this study illustrates that Trastuzumab can in-
duce regression in a HER-2 positive tumor, and that
PIK3CA mutation (in a HER-2 positive background)
may be a potential resistance mechanism to Trastuzu-
mab treatment in pre-clinical patient-derived EC xeno-
graft models. We believe that this pre-clinical
observation and hypothesis warrants further investiga-
tion in a clinical study.
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